INTEGRA LIFESCIENCES HOLDINGS CORP Q3 FY25 Results
IARTQ3 FY25 ResultsAnnounced Oct 30, 2025, 08:00 AM| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 402.06 | 3.3% | 5.6% |
| Total Income | 402.06 | 3.3% | 5.6% |
| Expenditure | 390.30 | 58.0% | 0.3% |
| PBT | -6.82 | 98.7% | 66.5% |
| Net Profit | -5.40 | 98.9% | 49.5% |
| OPM | 2.92% | 5.06pp | |
| NPM | -1.34% | 1.46pp | |
| EPS | -0.07 | 98.9% | 50.0% |
Integra LifeSciences Reports Q3 2025 Revenue Up 5.6% to $402.1 Million
04 May 2026 · 4 May, 8:30 am
Summary
Integra LifeSciences reported a 5.6% increase in third quarter revenues, reaching $402.1 million. Organic revenue grew by 5.0%. The company's GAAP earnings per diluted share was $(0.07), while adjusted earnings per diluted share was $0.54. The company is revising its 2025 guidance to reflect third quarter revenue and updated assumptions for the fourth quarter.
Key Highlights
- 1
Integra LifeSciences reported third quarter revenues of $402.1 million, an increase of 5.6% on a reported basis compared to the prior year.
- 2
Organic revenue increased by 5.0% compared to the third quarter of 2024.
- 3
The company's GAAP earnings per diluted share was $(0.07), compared to $(0.14) in the prior year.
- 4
Adjusted earnings per diluted share reached $0.54, compared to $0.41 in the prior year.
- 5
Adjusted EBITDA for the third quarter of 2025 was $78.5 million, or 19.5% of revenue, compared to $61.8 million, or 16.2% of revenue, in the prior year.
- 6
The company is revising its 2025 guidance to reflect third quarter revenue and updated assumptions for the fourth quarter.
- 7
Sales in Neurosurgery increased 13.3% on an organic basis driven by growth in Certas® Plus; DuraGen®; CereLink®; Mayfield capital in addition to a favorable prior year comparison.
Management Comments
Mojdeh Poul
“In the third quarter, we continued to see healthy demand across our portfolio. While revenue was impacted by two supply interruptions, we delivered strong profitability and cash flow through disciplined cost management and operational efficiencies.” “We are making progress in implementing our comprehensive plan to systematically strengthen the entirety of our supply chain and quality management system, and we remain confident in our strategy to improve overall performance and drive the Company’s transformation.”
Informational and educational content only. Not investment advice.